Drug Patents Expiring in 2041

1. List of Airduo Digihaler drug patents

AIRDUO DIGIHALER's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259

(Pediatric)

TEVA PHARM Drug delivery device with electronics and power management
Jan, 2041

(17 years from now)

US11266796 TEVA PHARM Inhalation device with integrated electronics
Feb, 2041

(17 years from now)

US11266796

(Pediatric)

TEVA PHARM Inhalation device with integrated electronics
Aug, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

5

United States

4

European Union

2

Spain

2

China

2

Japan

1

Australia

1

Israel

EA

1

EA

1

Korea, Republic of

1

Canada

2. List of Armonair Digihaler drug patents

ARMONAIR DIGIHALER's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259

(Pediatric)

TEVA PHARM Drug delivery device with electronics and power management
Jan, 2041

(17 years from now)

US11266796 TEVA PHARM Inhalation device with integrated electronics
Feb, 2041

(17 years from now)

US11266796

(Pediatric)

TEVA PHARM Inhalation device with integrated electronics
Aug, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

5

United States

4

European Union

2

Spain

2

China

2

Japan

1

Australia

1

Israel

EA

1

EA

1

Korea, Republic of

1

Canada

3. List of Austedo Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311488 TEVA Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
Jun, 2041

(18 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

4. List of Bylvay drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583539 ALBIREO Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
Nov, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2026
Orphan Drug Exclusivity (ODE) Jul 20, 2028

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 2025-07-20

Market Authorisation Date: 20 July, 2021

Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

5. List of Dapzura Rt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189 BAXTER HLTHCARE CORP Daptomycin formulations containing a combination of sorbitol and mannitol
Mar, 2041

(17 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 25 January, 2022

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DAPZURA RT family patents

5

United States

1

Australia

1

China

1

Canada

1

Brazil

6. List of Epidiolex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160795 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(17 years from now)

US11406623 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2023
Orphan Drug Exclusivity (ODE) Jul 31, 2027
New Patient Population (NPP) Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: 2022-09-28

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's patent expiration?
More Information on Dosage

EPIDIOLEX family patents

3

United States

3

United Kingdom

1

Australia

1

Taiwan

1

China

1

Korea, Republic of

1

Canada

1

Israel

1

European Union

7. List of Exparel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278494 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11179336 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11452691 PACIRA PHARMS INC Compositions of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11357727 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11311486 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11304904 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11033495 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11426348 PACIRA PHARMS INC Compositions of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Mar 22, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 28 October, 2011

Treatment: Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, f...

Dosage: INJECTABLE, LIPOSOMAL;INJECTION

How can I launch a generic of EXPAREL before it's patent expiration?
More Information on Dosage

EXPAREL family patents

12

United States

1

China

1

United Kingdom

1

European Union

8. List of Invega Hafyera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324751 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(17 years from now)

US11304951 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks ...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA HAFYERA before it's patent expiration?
More Information on Dosage

9. List of Lyvispah drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491125 AMNEAL Baclofen formulations and methods of minimizing patient exposure to metabolite variations
Sep, 2041

(18 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; Treatment of spasticity resulting from spin...

Dosage: GRANULES;ORAL

More Information on Dosage

10. List of Norliqva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458095 CMP DEV LLC NA
Feb, 2041

(17 years from now)

US11253474 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(17 years from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 24 February, 2022

Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; Norliqva is indicated for the symptomatic treatment of chronic stable ...

Dosage: SOLUTION;ORAL

More Information on Dosage

11. List of Opzelura drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11602536 INCYTE CORP Topical treatment of vitiligo by a JAK inhibitor
May, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 21, 2024
New Indication (I) Jul 18, 2025
Pediatric Exclusivity (PED) Mar 21, 2025

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: For the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, in the absence of laser or phototherapy, wherein the vitiligo affects at least one of the ...

Dosage: CREAM;TOPICAL

More Information on Dosage

12. List of Posimir drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400019 INNOCOLL Sustained release drug delivery systems with reduced impurities and related methods
Jan, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 1, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 01 February, 2021

Treatment: NA

Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION

More Information on Dosage

POSIMIR family patents

4

United States

1

Korea, Republic of

1

Canada

1

Brazil

1

European Union

13. List of Proair Digihaler drug patents

PROAIR DIGIHALER's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266796 TEVA BRANDED PHARM Inhalation device with integrated electronics
Feb, 2041

(17 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PROAIR DIGIHALER family patents

5

United States

4

European Union

2

Spain

2

China

2

Japan

1

Australia

1

Israel

EA

1

EA

1

Korea, Republic of

1

Canada

14. List of Qvar Redihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583643 NORTON WATERFORD Inhalers and related methods
Aug, 2041

(18 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

15. List of Tavneos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11603356 CHEMOCENTRYX Amorphous form of a complement component C5a receptor
May, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2028
New Chemical Entity Exclusivity (NCE) Oct 7, 2026

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: 2025-10-07

Market Authorisation Date: 07 October, 2021

Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids

Dosage: CAPSULE;ORAL

More Information on Dosage

16. List of Tlando drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464735 ANTARES PHARMA INC Fixed dose oral testosterone undecanoate compositions and use thereof
Apr, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: CAPSULE;ORAL

More Information on Dosage

17. List of Veklury drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 2024-10-22

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog...

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

VEKLURY family patents

4

United States

1

Taiwan

18. List of Vyleesi (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590209 PALATIN TECHNOLOGIES Use of bremelanotide in patients with controlled hypertension
Apr, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 21, 2024

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

NCE-1 date: 2023-06-22

Market Authorisation Date: 21 June, 2019

Treatment: Treating acquired, generalized hypoactive sexual desire disorder (hsdd) in a premenopausal female patient with controlled hypertension by injecting bremelanotide more than once with at least 24 hours ...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

19. List of Wegovy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11318191 NOVO GLP-1 compositions and uses thereof
Feb, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jun 4, 2024
New Patient Population (NPP) Dec 23, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

WEGOVY family patents

11

European Union

2

Australia

2

Canada

2

Argentina

2

Taiwan

2

China

2

Colombia

2

Korea, Republic of

2

Japan

2

Brazil

2

Israel

1

United States

20. List of Zimhi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571518 ADAMIS PHARMS CORP NA
Jun, 2041

(18 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; A method for administering a therapeutic dose of an opioid antagonist comprising an emerge...

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in